

Title (en)
ANTIBODY-DRUG CONJUGATE FORMULATION

Title (de)
ANTIKÖRPER-WIRKSTOFF-KONJUGAT-FORMULIERUNG

Title (fr)
FORMULATION DE CONJUGUÉ ANTICORPS-MÉDICAMENT

Publication
EP 4420729 A2 20240828 (EN)

Application
EP 24177039 A 20141121

Priority
• US 201361907001 P 20131121
• EP 14802428 A 20141121
• EP 2014075326 W 20141121

Abstract (en)
Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.

IPC 8 full level
A61P 35/00 (2006.01)

CPC (source: EP KR US)
A61K 9/19 (2013.01 - EP KR US); **A61K 31/047** (2013.01 - KR); **A61K 31/401** (2013.01 - KR); **A61K 39/39591** (2013.01 - EP US); **A61K 47/183** (2013.01 - KR); **A61K 47/22** (2013.01 - US); **A61K 47/26** (2013.01 - KR); **A61K 47/68031** (2023.08 - EP KR US); **A61K 47/6843** (2017.08 - EP KR US); **A61K 47/6889** (2017.08 - EP KR US); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 35/04** (2018.01 - KR); **C07K 16/2896** (2013.01 - KR); **C07K 16/36** (2013.01 - EP US); **A61K 47/183** (2013.01 - EP US); **A61K 47/26** (2013.01 - EP US); **C07K 2317/21** (2013.01 - EP US); **C07K 2317/565** (2013.01 - KR); **C07K 2317/77** (2013.01 - EP US); **C07K 2317/94** (2013.01 - US)

Citation (applicant)
• WO 2011157741 A2 20111222 - GENMAB AS, et al
• WO 9704801 A1 19970213 - GENENTECH INC [US]
• WO 9856418 A1 19981217 - GENENTECH INC [US]
• WO 0211753 A1 20020214 - CHUGAI PHARMACEUTICAL CO LTD [JP], et al
• WO 02096457 A2 20021205 - NOVARTIS AG [CH], et al
• WO 03009817 A2 20030206 - PROTEIN DESIGN LABS INC [US], et al
• WO 03039485 A2 20030515 - PROTEIN DESIGN LABS [US], et al
• US 8372396 B2 20130212 - ANDYA JAMES [US], et al
• WO 2004004639 A2 20040115 - SMITHKLINE BEECHAM CORP [US], et al
• WO 2004016286 A2 20040226 - ABBOTT LAB BERMUDA LTD, et al
• WO 2004055164 A2 20040701 - ABGENIX INC [US], et al
• WO 2004071439 A2 20040826 - ELAN PHARM INC [US], et al
• WO 2006014965 A2 20060209 - HUMAN GENOME SCIENCES INC [US], et al
• WO 2006044908 A2 20060427 - GENENTECH INC [US], et al
• WO 2007019232 A2 20070215 - IMMUNOGEN INC [US], et al
• WO 2007059782 A1 20070531 - GENMAB AS [DK], et al
• WO 2010066803 A2 20100617 - GENMAB AS [DK], et al
• US 6214345 B1 20010410 - FIRESTONE RAYMOND ARMAND [US], et al
• US 2005238649 A1 20051027 - DORONINA SVETLANA O [US], et al
• US 5635483 A 19970603 - PETTIT GEORGE R [US], et al
• US 5780588 A 19980714 - PETTIT GEORGE R [US], et al
• US 5663149 A 19970902 - PETTIT GEORGE R [US], et al
• WARD ET AL., NATURE, vol. 341, 1989, pages 544 546
• CHOTHIALESK J, MOL. BIOL, vol. 196, 1987, pages 901 917
• KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
• HOLT ET AL., TRENDS BIOTECHNOL, vol. 21, no. 11, November 2003 (2003-11-01), pages 484 - 90
• REVETS ET AL., EXPERT OPIN BIOL THER, vol. 5, no. 1, January 2005 (2005-01-01), pages 111 - 24
• BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 426
• HUSTON ET AL., PNAS USA, vol. 85, 1988, pages 5883
• "Genbank", Database accession no. NP_001984.1
• NEEDLEMANWUNSCH: "J. Mol. Biol.", vol. 48, 1970, pages: 443 - 453
• RICE ET AL., TRENDS GENET, vol. 16, 2000, pages 276 - 277
• CREIGHTON: "Proteins: Structure and Molecular Properties", 1993, W.H. FREEMAN AND COMPANY
• DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123
• SENTER ET AL., PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 45
• HENRY R. COSTANTINOMICHAEL J. PIKAL, LYOPHILIZATION OF BIOPHARMACEUTICALS
• LOUIS REYJOAN C. MAY, FREEZE DRYING / LYOPHILIZATION OF PHARMACEUTICALS AND BIOLOGICAL PRODUCTS
• ADITYA A. WAKANKAR ET AL., BIOCONJUGATE CHEMISTRY, vol. 21, no. 9, 2010, pages 1588 - 1595
• STEPHAN JP, BIOANALYSIS, vol. 3, no. 6, March 2011 (2011-03-01), pages 677 - 700
• WAKANKAR A ET AL., MABS, vol. 3, no. 2, March 2011 (2011-03-01), pages 161 - 72
• STEPHEN C ALLEYKEVIN E ANDERSON: "Analytical and bioanalytical technologies for characterizing antibody-drug conjugates", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 17, no. 3, June 2013 (2013-06-01), pages 406 - 411, XP055369650, DOI: 10.1016/j.cbpa.2013.03.022
• SINGH ET AL.: "Effect of Polysorbate 80 Quality on Photostability of a Monoclonal Antibody", AAPS PHARMSCITECH, vol. 13, no. 2, 2012, XP035064283, DOI: 10.1208/s12249-012-9759-6
• BRUCE A. KERWIN: "JOURNAL OF PHARMACEUTICAL SCIENCES", vol. 97, August 2008, article "Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: Structure and Degradation Pathways", pages: 2924 - 2935

- VASQUEZ-REYLANG: "Aggregates in monoclonal antibody manufacturing processes", BIOTECH, BIOENG, vol. 108, no. 7, 2011, pages 1494 - 1508

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2015075201 A1 20150528; BR 112016011441 A2 20170926; CN 106163567 A 20161123; CN 106163567 B 20210611; CN 113521016 A 20211022; DK 3071237 T3 20240909; EP 3071237 A1 20160928; EP 3071237 B1 20240626; EP 4420729 A2 20240828; FI 3071237 T3 20240923; JP 2016539118 A 20161215; JP 2019163319 A 20190926; JP 2021119199 A 20210812; JP 6590803 B2 20191016; JP 7162695 B2 20221028; KR 102372245 B1 20220308; KR 20160079890 A 20160706; MX 2016006488 A 20160803; PT 3071237 T 20240826; US 10617764 B2 20200414; US 2016279258 A1 20160929; US 2020246477 A1 20200806; US 2024091373 A1 20240321

DOCDB simple family (application)

EP 2014075326 W 20141121; BR 112016011441 A 20141121; CN 201480073804 A 20141121; CN 202110607250 A 20141121; DK 14802428 T 20141121; EP 14802428 A 20141121; EP 24177039 A 20141121; FI 14802428 T 20141121; JP 2016533019 A 20141121; JP 2019104081 A 20190604; JP 2021081392 A 20210513; KR 20167016066 A 20141121; MX 2016006488 A 20141121; PT 14802428 T 20141121; US 201415038235 A 20141121; US 202016742158 A 20200114; US 202218065196 A 20221213